Oishi A
Department of Surgery, Kansai Medical University, Osaka, Japan.
Nihon Geka Gakkai Zasshi. 1989 Oct;90(10):1742-51.
We examined the clinicopathological relevance of chromogranin immunoreactive cells in a well documented series of 212 large bowel cancer patients. Chromogranin immunoreactive cells were detected in 33.5% of the carcinomas, occurring either as rare cases (19.3%) or as diffuse cases (14.2%). The tumors with chromogranin immunoreactivity were associated with a more aggressive clinical course than tumors without immunoreactivity (Generalized-Wilcoxon; p less than 0.08). Moreover, the survival of patients with diffusely immunoreactive tumors was significantly shorter than that of patients without such cells (Generalized-Wilcoxon; p less than 0.009). Therefore, the study of chromogranin immunoreactivity in large bowel carcinomas may enable the identification of a subpopulation of colorectal carcinomas associated with a relatively poor prognosis.
我们在一组记录完备的212例大肠癌患者中，研究了嗜铬粒蛋白免疫反应性细胞的临床病理相关性。在33.5%的癌组织中检测到嗜铬粒蛋白免疫反应性细胞，表现为罕见病例（19.3%）或弥漫性病例（14.2%）。具有嗜铬粒蛋白免疫反应性的肿瘤比无免疫反应性的肿瘤临床病程更具侵袭性（广义威尔科克森检验；p<0.08）。此外，弥漫性免疫反应性肿瘤患者的生存期明显短于无此类细胞的患者（广义威尔科克森检验；p<0.009）。因此，研究大肠癌中的嗜铬粒蛋白免疫反应性，可能有助于识别出预后相对较差的结直肠癌亚群。
